迪敏康® utilizes the tNGS technology platform with proprietary techniques including homogenous cell disruption and pathogen databases, and reagent background bacteria monitoring to effectively reduce background nucleic acid interference and achieve deep sequencing of target regions. This service covers over 200 clinically significant pathogens and 16 core resistance genes, suitable for clustered/seasonal epidemics and suspected common infections of the respiratory system, central nervous system, and bloodstream infections; it supports a wide range of clinical fluids and tissue types.
